Pfizer have release a response to the disruption of Sayana® Press UK supply:
“We are currently experiencing an interruption in supply of Sayana® Press (medroxyprogesterone acetate 104mg/0.65ml suspension for injection in the Uniject™ injection system).
The temporary interruption of supply is due to a manufacturing issue at Pfizer’s manufacturing facility in Puurs, Belgium. In agreement with the Belgian Federal Agency for Medicines and Health Products (FAMHP), Pfizer has voluntarily temporarily interrupted manufacturing.
We are unable at this time to predict the duration of the supply interruption, but it is likely to be several months until the UK receives new stock. Pfizer continues to cooperate fully with FAMHP to minimize the impact to our customers and patients.
Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process.
We fully recognize the importance of Sayana® Press to patients and physicians and are working hard to resolve the supply shortage as quickly as possible.”